Furthermore, recent studies have shown that a A20 gene polymorphism was correlated with the efficacy of anti-TNF therapy in IBD patients (223, 224), indicating suggesting a link between abnormal A20 expression and immune activity. The gene discussed is TNFAIP3; the disease is inflammatory bowel disease.